COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03016338
Recruitment Status : Recruiting
First Posted : January 10, 2017
Last Update Posted : December 16, 2019
Tesaro, Inc.
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:
This is a phase 2 study of investigational drug niraparib and TSR-042 in patients with advanced/recurrent endometrial cancer. The purpose of this study is to determine whether blocking a protein called poly (ADP-ribose) polymerase (PARP) with niraparib provides clinical benefit in patients with recurrent endometrial cancer, as well as to explore the possible impact of phosphatase and tensin homolog (PTEN) loss (loss of function of the PTEN gene) on blocking PARP with niraparib.

Condition or disease Intervention/treatment Phase
Endometrial Cancer Drug: Niraparib Drug: TSR-042 Phase 2

Detailed Description:

The purpose of this trial is to elucidate whether the PARP inhibition approach with niraparib, or the combination of niraparib and TSR-042, provides clinical benefit in patients with recurrent endometrial cancer.

The trial is designed as a multicenter, open-label, phase II study of niraparib in monotherapy or in combination with anti-PD1 inhibitor TSR-042 in recurrent endometrial cancer. Patients must have received prior platinum based chemotherapy.

The study will initially enroll patients with recurrent endometrial cancer to the niraparib monotherapy cohort not selected according to the PTEN status (cohort I).

Once the initial assessment with niraparib monotherapy is completed (inclusion of 22 evaluable patients),Additional 22 patients will be enrolled in the combination arm with niraparib and TSR-042 (cohort II).

Eligible participants will take niraparib capsules or tablets by mouth 300/200 mg, once a day, every day of every 21 day cycle.Participant will receive TSR-042 500 mg( intravenously) on the first day of each cycle for cycle 1 to 4. Followed by 1000 mg every 2 cycle for every 6 weeks for maximum of 2 yrs.

While receiving the study treatment, participants will be asked to visit the study site on Days 1, 8, 15 of Cycle 1.Cycle 2 onward Days 1 and 15 and future cycles for safety tests and procedures. If, at any time, participants develop (or is suspected to have developed) MDS/AML, a mandatory bone marrow aspirate/biopsy will be done for testing to confirm diagnosis.

When participants are taken off the study treatment permanently, they will be asked to return to the study site for an End of Study Treatment visit to have tests and procedures done for safety purposes.

Participants who are taken off the study treatment for any reason other than disease progression will continue to have radiological assessments every 8 weeks until disease progression. Participants will continue to be followed up for side effects weekly in the first 4 weeks, then monthly until resolution.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Open Label Study of the Poly(ADP-ribose) Polymerase Inhibitor Niraparib in Monotherapy or in Combination With Anti-PD1 Inhibitor TSR-042 in Recurrent Endometrial Cancer
Actual Study Start Date : November 6, 2017
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Niraparib +TSR-042
200/300 mg Niraparib by mouth once a day for 21 days cycle. 500 mg of TSR-042 intravenously on the first day of each cycle.
Drug: Niraparib
200 or 300 mg daily PO, for 21 day cycle
Other Name: MK4827

Drug: TSR-042
500 mg once intravenously on day 1 of cycle (From cycle 1-4 followed by 1000 mg intravenously every 6 weeks for maximum of 2 yrs)

Primary Outcome Measures :
  1. Clinical benefit rate [ Time Frame: 16 weeks ]

Secondary Outcome Measures :
  1. Number of side effects [ Time Frame: 5 years ]
  2. Overall response rate [ Time Frame: 5 years ]
  3. Duration of response [ Time Frame: 5 years ]
  4. Progression free survival rate [ Time Frame: 5 years ]
  5. Overall survival rate [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed epithelial endometrial cancer. All histological subtypes are allowed except for endometrial sarcoma, carcinosarcoma, clear cell, mixed and adenosquamous tumors.
  • Patients must have radiographic evidence of disease progression following the most recent line of treatment.
  • Patients must have previously received at least one line of platinum-based chemotherapy. Prior hormonal and immunotherapy are allowed. There is no restriction on the total number prior lines of therapy.
  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥10 mm with CT scan, MRI, or calipers by clinical exam, and ≥15mm for nodal lesions. Areas of previous radiation may not serve as measurable disease unless there is evidence of progression post radiation.
  • Patients must have archival tumor sample available for PTEN analysis. If archival tissue is not available, the patient will have the option to undergo tumor biopsy.
  • Eastern Cooperative Group (ECOG) performance status ≤ 2.
  • Life expectancy of greater than 12 weeks.
  • Within 7 days of the proposed start of treatment, patients must have normal organ and marrow function.
  • Participant receiving corticosteroids may continue as long as their dose is stable for at least 4 weeks prior to initiating protocol therapy
  • Patient must agree to not donate blood during the study or for 90 days after the last dose of study treatment

Exclusion Criteria:

  • Chemotherapy or biologic agents received within 4 weeks of starting study treatment.
  • Hormonal therapy within 2 weeks of starting study treatment.
  • Pelvic radiotherapy (as treatment of primary disease) within 4 weeks, or palliative radiotherapy encompassing >20% of the bone marrow within 1 week of starting study treatment.
  • Previous treatment with a PARP inhibitor, or any other targeted therapy directed against the homologous recombination pathway.
  • Patients who are receiving any other investigational agents.
  • Ongoing ≥ Grade 2 toxicities related to prior cancer therapy, with the exceptions of alopecia, neuropathy, lymphopenia and skin depigmentation.
  • Received transfusion (platelets or red blood cells) ≤4 weeks of the first dose of study treatment.
  • Major surgery within 4 weeks of registration or ongoing clinically significant post-surgical complications. Study biopsy is not considered major surgery.
  • Known brain metastases, except if stable for greater than 28 days following definitive treatment. The patient must have no new or progressive signs or symptoms related to the CNS disease and must be either off or taking a stable dose of corticosteroids. A scan to confirm the absence of brain metastases is not required.
  • History of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML).
  • History of bowel obstruction within 3 months, or other reason preventing effective oral administration of medication.
  • Immunocompromised patients e.g. Human Immunodeficiency Virus (HIV) requiring treatment or active Hepatitis B or C. Prior splenectomy is allowed.
  • Uncontrolled inter-current illness.
  • History of other malignancy ≤ 3 years prior to registration with the exceptions of a) cone-biopsied in situ carcinoma of the cervix uteri; b) basal or squamous cell carcinoma of the skin. All second malignancies in this context should be discussed with the Principal Investigator.
  • Previous treatment with anti PD-1, anti PD-L1, anti PD-L2, anti CTLA4 agents
  • History of fistula, or high-risk of developing a fistula.
  • Diagnosis of immunodeficiency or systemic steroid therapy or other form of immunosuppressive therapy within 7 days prior to initiating the protocol therapy.
  • Known history of human immunodeficiency virus (type 1 or 2 antibodies).
  • Known active hepatitis (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative] is detected).
  • Active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs) Replacement therapy eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • History of interstitial lung disease
  • Received a live vaccine within 14 days of initiating protocol therapy
  • History of ≥ Grade 3 immune-related AE with prior immunotherapy, with the exception of non-clinically significant lab abnormalities.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03016338

Layout table for location contacts
Contact: Stephanie Lheureux, M.D. 416-946-2818
Contact: Amit M Oza, M.D. 416-946-2818

Layout table for location information
Canada, Alberta
Tom Baker Cancer Centre Recruiting
Calgary, Alberta, Canada, T2N 4N2
Contact: Prafull Ghatage, M.D.    403-521-3721      
Principal Investigator: Prafull Ghatage         
Canada, Ontario
Juravinski Cancer Centre Active, not recruiting
Hamilton, Ontario, Canada, L8V 5C2
Cancer Centre of Southeastern Ontario at Kingston Recruiting
Kingston, Ontario, Canada, K7L 5P9
Contact: Jim Biagi, M.D.    613-44-2630      
Principal Investigator: Jim Biagi, M.D.         
London Regional Cancer Centre Recruiting
London, Ontario, Canada, N6A 4L6
Contact: Stephen Welch, M.D.    519-685-8640      
Sunnybrook Research Institute, Sunnybrook Health Sciences Centre Recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Helen MacKay, M.D.    416-480-5145      
Principal Investigator: Helen MacKay, M.D.         
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada, M5G 1M9
Contact: Stephanie Lheureux, M.D.    416-946-2818      
Principal Investigator: Stephanie Lheureux, M.D.         
Canada, Quebec
McGill University Health Centre - Glen Site Recruiting
Montréal, Quebec, Canada, H3A 3J1
Contact: Lucy Gilbert, M.D.    514-934-1934 ext 34049      
Principal Investigator: Lucy Gilbert, M.D.         
Sponsors and Collaborators
University Health Network, Toronto
Tesaro, Inc.
Layout table for investigator information
Study Director: Amit M Oza, M.D. UHN - Princess Margaret Cancer Centre
Layout table for additonal information
Responsible Party: University Health Network, Toronto Identifier: NCT03016338    
Other Study ID Numbers: NEC
First Posted: January 10, 2017    Key Record Dates
Last Update Posted: December 16, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Genital Diseases, Female
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents